Trial Sponsored by:

NHS Greater Glasgow and Clyde




  • NHS Greater Glasgow and Clyde

Chief Investigator        


Trial Project Manager

Trial Summary

VSPI: Markers and Mediators of Angiogenesis Inhibitor-Induced Vascular and Myocardial Toxicity: Prospective Study in Patients with Cancer

Advancements in cancer treatments in recent years have led to increased survival for many patients. Vascular endothelial growth factor-signalling pathway inhibitors (VSPIs) have accounted for some of this success and are now used in a range of malignancies. However, VSPIs are associated with cardiovascular toxicities including hypertension and heart failure.

The aims of this study are to characterise the vascular and myocardial effects of VSPIs at a macro- and microvascular level and to identify the mechanisms underlying these cardiovascular toxicities in order to identify pathophysiologically-targeted treatments.

Patient Recruitment

Recruitment status: Completed

Key Links & Engagement


Press releases: